Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Apr 13, 2022 5:58pm
138 Views
Post# 34602013

RE:RE:RE:RE:RE:RE:Quick Summary

RE:RE:RE:RE:RE:RE:Quick Summary

All JFM is doing is bemoaning the lack of clinical trial data. I don't see anybody, even SPCEO, countering that. What do you do once you realize you don't have the data you really want? Seems to me SPCEO goes looking for other things (like the ex-Pfizer advisor being onboard). Something both Jfm and me don't do so much. Maybe the differences of opinion comes from looking at the problem from different angles.


SPCEO1 wrote: What is incredible is that you apparently cannot read very well. Stop distorting and try to actually add some value to this top flight message board. We are all happy here to debate whatever negative sceario you want to put forward as we do alot of that already. I am not sure what purpose distorting things serves though.
 

Momo25 wrote: Every argument JFM made about his disappointment and dissatisfaction in regard with the company attitude and its evident absence of communication is faced by a counter argument from Speceo who made his feet in Paul Lvesque shoes. Incredible ! isn't it ?




<< Previous
Bullboard Posts
Next >>